



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/15

22nd May, 2026

**Corporate Relationship Department
BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

**Listing Department
National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Press Release

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Press Release of the Gujarat Themis Biosyn Limited ('the Company') for acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. ("MBJ"), Japan, through Themis Biosyn Japan Limited, a wholly owned Subsidiary incorporated in Japan.

Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

Dinesh S. Patel
Chairman & Director
DIN: 00033273

Press Release

Gujarat Themis Biosyn Limited (GTBL) to acquire MicroBiopharm Japan Co., Ltd. (MBJ), Accelerates GTBL's Transition to a Fermentation-based Globally Integrated CDMO Platform

Mumbai, May 22, 2026 – Gujarat Themis Biosyn Ltd., amongst the leading pharmaceutical companies with established capabilities in fermentation-based intermediates and active pharmaceutical ingredients (APIs), has announced the signing of definitive agreement for the acquisition of 100% equity shareholding of MicroBiopharm Japan Co., Ltd. from funds managed or advised by T Capital Partners Co., Ltd., a Japan based Private Equity Fund.

The acquisition will be executed through a wholly owned special purpose vehicle (SPV) to be incorporated in Japan. The transaction is expected to close during Q2FY27, subject to customary approvals and closing formalities.

This acquisition represents a significant milestone in GTBL's long-term strategy to evolve from a fermentation-led intermediates business into a technology-driven Contract Development Manufacturing Organization (CDMO) platform with capabilities across precision fermentation, biotechnology, and next-generation drug manufacturing.

MBJ is an established Japanese company with over six decades of experience in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals. The company operates a compelling platform spanning from manufacturing proprietary pharmaceuticals to CDMO services. It has recorded an estimated revenue of JPY 9.5 billion (approximately INR 570 crores) for FY26E.

MBJ's proprietary pharmaceuticals includes the manufacturing of oncology, immunosuppressants, antibiotics and peptides. It offers end-to-end CDMO capabilities in both small molecules and biologics. CDMO services encompasses discovery, development, manufacturing, leveraging its strengths in microbial fermentation, chemical synthesis, and biologics, including recombinant proteins.

Strategic Rationale for the Acquisition

- **Complementary capabilities** – MBJ will significantly add to GTBL's fermentation capabilities by providing access to precision fermentation technologies
- **Unique Proprietary Technologies** – Access to MBJ's P450 enzyme library, Plasmid DNA technology, ADC Conjugation technology and strain and process optimization technology
- **Manufacturing of Proprietary pharmaceuticals of MBJ** – Oncology, immunosuppressants, antibiotics and peptides. GTBL to provide access to Indian manufacturing capabilities and capacities
- **Long-standing relationships** with leading Japanese and international pharmaceutical companies
- **Global diversified platform:** Proprietary pharmaceuticals and non-pharma products account for over 47% of total revenue for FY26E, with balance largely contributed by CDMO services. Approximately 40% of revenue is derived from overseas market outside Japan
- **Scalable, GMP-compliant manufacturing and regulatory access:** Two of the three sites in Japan with track record of FDA and PMDA audit, enabling expanded access to regulated markets globally. GTBL's expanded manufacturing capacities to complement MBJ's global delivery
- **Value creation through cost, technology, and portfolio expansion:** Step-change in cost competitiveness via GTBL-MBJ integration of Fermentation technologies, expansion into manufacturing of oncology APIs and advanced modalities (ADCs, plasmids)
- **Strong management** - Experienced Management with strong scientific background and association with academia

Commenting on the development, Dr. Sachin Patel, Managing Director, GTBL, said:

“This acquisition marks a strategic step in GTBL’s evolution toward a next-generation, discovery-led CDMO platform. MBJ’s differentiated fermentation and biotechnology capabilities, combined with its strong regulatory track record and scalable infrastructure, significantly enhance our ability to serve global customers across advanced and emerging therapeutic modalities. By integrating MBJ’s platform with our existing strengths in fermentation and process innovation, we aim to build a globally competitive, high-margin pharmaceutical manufacturing and services business, anchored in long-term growth and value creation.

I would like to take this opportunity to assure that we will continue and build on MBJ’s current capabilities, leadership, management and strong base of employees and associates as we scale new horizons leading to mutual growth and success”

The consideration for the transaction would be approximately JPY 21.5 billion (approximately INR 1,300 crores), payable at closing, and is expected to be funded through an optimal mix of debt and equity. The acquisition is expected to be EPS accretive.

About Gujarat Themis Biosyn Limited

GTBL is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specializes in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform. <https://www.gtbl.in/>

About MicroBiopharm Japan Co., Ltd.

MBJ is a Japan-based pharmaceutical company engaged in the research, development, and manufacturing of APIs, intermediates, and contract development and manufacturing (CDMO) services. The company has established strong capabilities in microbial fermentation and biotechnology-based manufacturing and offers a diversified portfolio spanning oncology APIs, plasmid DNA manufacturing, ADC conjugation, and enzyme-based bioconversion platforms.

About T Capital Partners Co., Ltd.

T Capital Partners is a Japan-based private equity investment firm focused on supporting the sustainable growth and transformation of mid-market companies across a wide range of industries. Since establishing its fund management business in 1998, T Capital Partners has invested in numerous companies, working closely with management teams to drive operational improvement, business expansion, and long-term value creation through a partnership-driven and hands-on investment approach.

For further information, please contact :

Gujarat Themis Biosyn Limited Mr. Krupesh Patel Chief Financial Officer krupesh.patel@themismedicare.com	Investor Relations – Adfactors PR Mr. Rahul Trivedi rahul.trivedi@adfactorspr.com Ms. Saloni Nagvekar saloni.nagvekar@adfactorspr.com
--	--